Biohub, DOE, NIH, Google DeepMind, Meta and research partners pledge $1.8B for an open-source AI virtual cell. Read more: Explore the initiative's goals.
A Dutch court barred Merck from making or selling Keytruda SC in eight European markets, ruling in Halozyme’s patent dispute. Read what the order means now.
SurVaxM missed its overall survival endpoint in glioblastoma, but patients 65 and younger saw a significant benefit. Read the trial results and context.
Matchpoint Therapeutics raised $150 million in Series B funding to advance MPT-062 toward clinical proof of concept. Explore the investors and pipeline.
EPI-321 data show increased lean muscle volume and strength after six months in six people with FSHD. Read the full Phase I/II study results and updates.
Telomir Pharmaceuticals raised $5.6 million in PIPE funding to advance Telomir-Zn toward a first-in-human TNBC trial. Read the latest funding update now.
Kairos Pharma’s Phase II mCRPC data show ENV-105 plus apalutamide extended median PFS to 17.7 months versus 2 months. Read ...
KymaThera raised $80 million in Series B funding to advance K-1728, an oral pan-mutant selective PI3Kα inhibitor. Read what ...
Zag Bio’s ZAG-101 enters a first-in-human trial for type 1 diabetes. Explore the Phase Ib/IIa LANTERN study and its planned enrollment of adults today.
Vaxcyte is raising $1 billion through stock, warrants and convertible notes to advance its VAX-31 pneumococcal vaccine. Read the full offering details now.
A Phase III trial will test MRD-guided giredestrant and CDK4/6 inhibitor use in early breast cancer. Explore the study design and its potential impact.
FDA grants Priority Review to BridgeBio's oral infigratinib NDA for children with achondroplasia. Explore the treatment, FDA timeline and next steps now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results